Avadel Pharmaceuticals plc (AVDL)
NASDAQ: AVDL · IEX Real-Time Price · USD
17.81
-0.01 (-0.06%)
At close: Apr 26, 2024, 4:00 PM
18.04
+0.23 (1.29%)
After-hours: Apr 26, 2024, 7:15 PM EDT
Avadel Pharmaceuticals Employees
Avadel Pharmaceuticals had 154 employees on December 31, 2023. The number of employees increased by 113 or 275.61% compared to the previous year.
Employees
154
Change (1Y)
113
Growth (1Y)
275.61%
Revenue / Employee
$181,578
Profits / Employee
-$1,040,753
Market Cap
1.61B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 154 | 113 | 275.61% |
Dec 31, 2022 | 41 | -25 | -37.88% |
Dec 31, 2021 | 66 | 34 | 106.25% |
Dec 31, 2020 | 32 | -18 | -36.00% |
Dec 31, 2019 | 50 | -94 | -65.28% |
Dec 31, 2018 | 144 | -36 | -20.00% |
Dec 31, 2017 | 180 | -12 | -6.25% |
Dec 31, 2016 | 192 | 83 | 76.15% |
Dec 31, 2014 | 109 | -142 | -56.57% |
Dec 31, 2013 | 251 | -5 | -1.95% |
Dec 31, 2012 | 256 | -11 | -4.12% |
Dec 31, 2011 | 267 | -24 | -8.25% |
Dec 31, 2010 | 291 | -11 | -3.64% |
Dec 31, 2009 | 302 | 18 | 6.34% |
Dec 31, 2008 | 284 | -18 | -5.96% |
Dec 31, 2007 | 302 | -4 | -1.31% |
Dec 31, 2006 | 306 | 47 | 18.15% |
Dec 31, 2005 | 259 | 35 | 15.63% |
Dec 31, 2004 | 224 | 50 | 28.74% |
Dec 31, 2003 | 174 | 24 | 16.00% |
Dec 31, 2002 | 150 | 12 | 8.70% |
Dec 31, 2001 | 138 | 1 | 0.73% |
Dec 31, 2000 | 137 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Addus HomeCare | 34,846 |
U.S. Physical Therapy | 6,720 |
Warby Parker | 3,491 |
UFP Technologies | 3,093 |
Myriad Genetics | 2,700 |
Zai Lab | 2,175 |
Taro Pharmaceutical Industries | 1,554 |
Supernus Pharmaceuticals | 652 |
AVDL News
- 26 days ago - Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Avadel Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Avadel Pharmaceuticals Issues Statement On Patent Litigation - GlobeNewsWire
- 7 weeks ago - Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 6 months ago - Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results - GlobeNewsWire
- 6 months ago - Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 2023 - GlobeNewsWire
- 7 months ago - Avadel Pharmaceuticals to Present at the Jefferies Biotech CNS/Neuro Summit - GlobeNewsWire
- 9 months ago - Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results - GlobeNewsWire